Feighner 1989.

Methods	1. Randomized 2. Double blind 3. Two parallel groups: ‐placebo ‐Buspirone 10mg‐60mg/d Six double‐blind studies were pooled from the FDA‐approved New Drug Application database for buspirone 4. Duration: 4 weeks with 4‐7 day waskout period 5. Analysis: ANOVA
Participants	1. Diagnosis: GAD (DSM‐III) 2. N = 459 3. Age (mean): placebo = 38.4 Buspirone = 39.3 Sex: 64% females Setting: outpatients History: excluded any significant psychiatric disorder other than GAD
Interventions	1. Placebo (N = 225) 2. Buspirone (N = 234)
Outcomes	1. HAM‐A 2. Covi Anxiety Scale 3. Raskin Depression Scale
Notes	HAM‐A not entered into final analysis as means and SDs not reported
Risk of bias
Bias	Authors' judgement	Support for judgement
Allocation concealment (selection bias)	Unclear risk	B ‐ Unclear